Ivan Bergstein, M.D. Chief Executive Officer	Prior to founding Stemline, Dr. Bergstein was Medical Director of Access Oncology, Inc. (now Keryx Biopharmaceuticals, Inc. [Nasdaq: KERX]) where he was a key member of the team that in-licensed and developed several clinical stage oncology compounds. Prior to this, he was senior biopharmaceuticals analyst at Cancer Advisors (now Nitron Advisors), a Wall Street-based firm that advises investment funds on public oncology-focused companies. He received a B.A. in mathematics from the University of Pennsylvania, an M.D. from the Mount Sinai Medical Center, and completed an internal medicine residency and hematology-medical oncology fellowship at the New York Presbyterian Hospital-Weill Medical College of Cornell University.
Thomas P. Cirrito, Ph.D. Director of Operations	Prior to joining Stemline, Dr. Cirrito was a biopharmaceuticals equities analyst at Piper Jaffray, where he covered large and small cap biotechnology companies. Previously he was a life sciences consultant for A.G. Edwards Capital Partners, a venture capital group . He received a B.A. in Biological Sciences and a Ph.D. in Immunology from Washington University (St. Louis, MO).

Geoffrey Yarranton, Ph.D.
Chief Scientific Officer
Kalobios Pharmaceuticals, Inc. (Palo Alto, CA)

Francis Giles, M.D.
University of Texas Health Science Center (San Antonio, TX)

Fred Appelbaum, M.D.
Fred Hutchinson Cancer Center (Seattle, WA)

Charles Schiffer, M.D.
Wayne State University (Detroit, MI)